Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 868 results for "for merck"

Merck obtains FDA approval for grass pollen allergy drug
Pharmaceutical Technology

Merck receives FDA approval for ragweed pollen-induced allergi...

Merck has received FDA approval for RAGWITEK tablet for sublingual use, indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing ... Individual.com, 22 hours ago
Merck gets another allergy drug in its quiver Seeking Alpha, 1 day ago
[x]  

827 images for for merck

Pharma Times, 1 day ago
FOXNews.com, 1 day ago
InvestorPlace.com, 3 days ago
Health Impact News, 3 days ago
WorldPoultry.net, 4 days ago
Pharma Letter, 4 days ago
Medical Marketing And Media, 1 week ago
WYFF4.com, 1 week ago
WYFF4.com, 1 week ago
Site Selection Magazine, 1 day ago

Auxogyn enters into licensing agreement with Merck Serono

(MarketLine via COMTEX News Network) -- Auxogyn, Inc., a provider of products for women's reproductive health, has entered into an exclusive licensing agreement with Merck Serono, the biopharmaceutical division of Merck KGaA, for Auxogyn's ...
 PredictWallStreet22 hours ago Embryo test becomes Merck's new baby  Pharma Field1 week ago

Merck extends AZ offer again over Chinese antitrust issues

FRANKFURT, April 18 (Reuters) - German liquid crystal maker Merck KGaA extended the offer period for its planned takeover of AZ Electronic Materials for a sixth time on Friday as it continues to seek Chinese antitrust approval.The offer period has ...
 London South East20 hours ago UPDATE 1-Merck extends AZ offer again over Chinese antitrust issues  Reuters18 hours ago
[x]  
Medical Marketing And Media

Will Merck & Co. Inc Unseat Biotech's Hottest Drug?

No drug has hit the market running like Gilead Sciences ' ( NASDAQ: GILD ) freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory ...
 Motley Fool1 day ago Merck's Hepatitis C Pill Competes with Gilead  Telemanagement1 week ago Why Merck (MRK) Stock Is Higher This Morning  TheStreet.com1 week ago Merck Hepatitis C combo pill impresses in Phase II  Seeking Alpha1 week ago
[x]  

Merck (MRK) Trading Near $57.40 Resistance Level

After closing Wednesday at $56.26, Merck & Co Inc. (http://www.marketintelligencecenter.com/symbol/MRK"MRK) presents an attractive opportunity to get a 2.69% return in just 65 days, which is an annualized return of 15.10% (for comparison purposes ...
 Individual.com1 day ago Merck (MRK) Trading Near $57.23 Resistance Level  Individual.com4 days ago Merck (MRK) Trading Near $55.68 Support Level  Individual.com1 week ago

Merck Serono's President & CEO Belén Garijo has Been Appointed to Board of Directors of L'Oréal

/PRNewswire/ -- Merck Serono, the biopharmaceutical division of Merck, announced today that Belén Garijo, President & Chief Executive Officer of Merck Serono, has been appointed as an independent Director of L'Oréal for a period of four years.
 Yahoo! Finance1 day ago Belén Garijo, Présidente-Directrice Générale de Merck Serono, est nommée au Conseil d'Administration...  BioMedReports1 day ago Belén Garijo, President und CEO von Merck Serono, in den Verwaltungsrat von L'Oréal berufen  BioMedReports1 day ago Merck Serono's President & CEO Bel??n Garijo Has Been Appointed To Board Of Directors Of  BioSpace19 hours ago
[x]  

04.17.14 -- Pfizer, Novartis, Merck, And GSK Experts Offer Advice On Supply Chain Management

SPONSOR Share Your Feedback on Blister and Bottle Packaging; Chance to Win iPad Air Have you taken our 90-second survey? We want to understand your initiatives and challenges in bottle and blister packaging services so we can ...
 Pharmaceutical Online1 day ago
Bidness Etc

Merck announces encouraging interim results from Phase II hepatitis C study

Merck has announced interim results from the ongoing C-WORTHy study, a multi-arm Phase II clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A ...
 Individual.com3 days ago Merck announces encouraging data from Phase II hepatitis C virus studies  Individual.com5 days ago As Hep C Cure Rate Hits 98%, Merck Challenges Gilead  Yahoo! Finance1 week ago HCV Rivalry Heats Up As Merck Combo Shines In Trial  Investor's Business Daily1 week ago
[x]  

Merck (MRK) Crosses Pivot Point Resistance at $56.54

Shares of Merck (NYSE:MRK) opened today above their pivot of $55.82 and have already reached the first level of resistance at $56.54. Analysts will be watching for a cross of the next upside pivot targets of $57.02
 Individual.com2 days ago Next Resistance Level for Merck (MRK) is $57.23  Individual.com4 days ago Merck (MRK) Approaches New Upside Target of $56.03  Individual.com1 week ago

Merck (MRK) Showing Resistance Near $57.02

Merck & Co Inc. (http://www.marketintelligencecenter.com/symbol/MRK"MRK) presents a trading opportunity that offers a 2.88% return in just 66 days. A covered call on Merck at the $55.00 level expiring on Jun. '14 offers an assigned return rate of ...
 Individual.com2 days ago Merck (MRK) Showing Neutral Technicals With Resistance At $57.53  Individual.com3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less